BlackRock Virginia Municipal Bond Trust
Change company Symbol lookup
Select an option...
BHV BlackRock Virginia Municipal Bond Trust
JNJ Johnson & Johnson
TRQ Turquoise Hill Resources Ltd
STAA STAAR Surgical Co
PRPL Purple Innovation Inc
INTC Intel Corp
PSB PS Business Parks Inc
GWRE Guidewire Software Inc
UYM.TC ProShares Ultra Basic Materials ETF
DKS Dick's Sporting Goods Inc

Company profile

BlackRock Virginia Municipal Bond Trust (the Trust) is a closed-end management investment company. The Trust's investment objective is to provide current income exempt from regular U.S. federal income tax and Virginia personal income taxes. It invests primarily in municipal bonds exempt from U.S. federal income taxes and Virginia personal income taxes. The Trust invests, under normal market conditions; at least 80% of its managed assets in municipal bonds that are investment grade quality at the time of investment or, if unrated, determined to be of comparable quality at the time of investment by the Trust's investment adviser. The Trust may invest directly in such securities or synthetically through the use of derivatives.

Closing Price
Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low

10-day average volume:

Lilly Announces Leadership Changes

6:30 am ET September 9, 2020 (PR Newswire) Print

Eli Lilly and Company (NYSE: LLY) announced today that Patrik Jonsson, senior vice president and president of Lilly Bio-Medicines, is being named to the new role of senior vice president, president of Lilly USA, and Chief Customer Officer. In a related move, Ilya Yuffa, currently vice president of U.S. Diabetes, is being promoted to senior vice president and will succeed Jonsson as senior vice president and president of Lilly Bio-Medicines. Both Jonsson and Yuffa will report to David A. Ricks, Lilly chairman and chief executive officer, and be members of Lilly's executive committee. The changes are effective October 1, 2020.

"With a number of new medicines expected to launch in important therapeutic areas over the next several years, Lilly has a tremendous opportunity to serve many more patients in the U.S. and provide industry-leading customer support," Ricks said. "Now is the time to name a dedicated executive to lead Lilly USA and our global customer-focused functions during this time of exciting growth. Patrik is an enterprise leader with a long track record of successfully managing Lilly businesses in complex markets around the world. During his time as president of Lilly Bio-Medicines, Patrik has kept our customers and the patients that rely on our medicines at the forefront of our strategy, delivered strong results and left solid footprints from his tenure. He is uniquely qualified to take on this new leadership role."

Jonsson joined Lilly in 1990 as a sales representative in Sweden after earning an MBA from Lund University. He held numerous positions of ascending leadership internationally for most of his career, including general manager of Sweden, Scandinavia, Italy, and Japan. Jonsson was promoted to his current position of senior vice president and president of Lilly Bio-Medicines in 2019.

"Lilly Bio-Medicines is now home to a growing portfolio of new medicines and a pipeline of next generation molecules spanning immunology, pain and neurodegeneration that will be critical to the future success of our company," added Ricks. "Ilya's effective leadership of our largest U.S. franchise, U.S. Diabetes, and his broad experience across many parts of our business have prepared him well to lead Lilly Bio-Medicines."

Early in his 25-year Lilly career, Yuffa held roles in finance and business development, and earned his MBA from the London Business School. He later served in sales and general leadership roles across the enterprise and held senior level positions in the company's six sigma and ethics and compliance organizations. Before assuming leadership for U.S. Diabetes in 2018, Yuffa served as general manager of Italy.

About Eli Lilly and Company Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at


This press release contains forward-looking statements about leadership changes and reflects Lilly's current beliefs. There are risks and uncertainties related to leadership changes. For discussion of important risks and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

Refer to: Mark Taylor;; (317) 276-5795 (Media)
          Kevin Hern;; (317) 277-1838 (Investors)

View original content to download multimedia:

SOURCE Eli Lilly and Company

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.